This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck to Settle Vioxx Lawsuits

"We have done everything humanly possible to ensure that it actually resolves the vast majority of myocardial infarction and ischemic stroke cases, to close the doors to new filings and to guard against fraud," said General Counsel Bruce Kuhlik.

Payment to individual claimants could start as early as next August. Merck said it expects to record a fourth-quarter pretax charge of $4.85 billion to cover the cost of the agreement. The company expects the charge will be tax deductible.

Natixis Bleichroeder analyst Jon LeCroy said he expects the payment to reduce interest income by about $200 million a year going forward. Also updating his predictions for Merck's Gardasil, he noted, "For 2007 and 2008, interest income losses offset the vaccine increases, leading to lower EPS estimates. For 2009-2011, however, the vaccine increases more than offset lower interest income and EPS increase."

LeCroy has a buy rating and is now looking for 2007 EPS of $3.15, a penny lower than his previous estimate, and $3.46, $3.79 and $4.26 in '08, '09 and '10, respectively. Prior estimates were for $3.50, $3.74 and $4.21 for 2008-2010.

For Trotta's video take on Merck's Vioxx settlement, click here.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $54.84 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs